New targets and new treatments in non-small cell lung cancer

European Journal of Cancer, Supplement

Volumn 2, Issue 4, 2004, Pages 1-6

  Johnson, B E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis inhibitors; Carcinoma, non small cell; Genes, erbB 2; Lung neoplasm; Matrix metalloproteinase; Receptor, genes, erbB 1

Indexed keywords

AE 941; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AZELASTINE; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLONTINIB; GEFITINIB; GEMCITABINE; ISIS 3521; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; OBLIMERSEN; PACLITAXEL; PRINOMASTAT; PROTEIN KINASE C ALPHA; REBIMASTAT; TANOMASTAT; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 2442459061     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2003.11.001     Document Type: Article

References (27)

1. Cullen M.H., Billingham L.J., Woodroffe C.M., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer effects on survival and quality of life. J. Clin. Oncol. 17:1999;3188-3194
2. Group TELCVIS. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J. Natl. Cancer Inst. 91:1999;66-72
3. Breathnach O.S., Freidlin B., Conley B., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer sobering results. J. Clin. Oncol. 19:2001;1734-1742
4. Kelly K., Crowley J., Bunn P.A. Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer a Southwest Oncology Group trial. J. Clin. Oncol. 19:2001;3210-3218
5. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:2002;92-98
6. Bunn P.A. Jr., Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin. Oncol. 29:(Suppl. 14):2002;38-44
7. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors results of a phase I trial. J. Clin. Oncol. 20:2002;3815-3825
8. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19:2001;3267-3279
9. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
10. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer a randomized trial. JAMA. 290:2003;2149-2158
11. Perez-Soler R., Chachoua A., Huberman M., et al. A phase II trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774, follo wing platinum-based chemotherapy in patients with advanced, EGFR-expressing, non-small cell lung cancer. Grunberg S.M. Annual Meeting of the American Society of Clinical Oncology; 2001. 2001;310a American Society of Clinical Oncology, Orlando, FL
12. Johnson D.H., Herbst R., Giaccone G., et al. ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer results from a phase III randomized trial (INTACT 2). Kerr D.J. European Society of Medical Oncology Congress; 2002. 2002;128 Oxford University Press, Nice, France
13. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Kerr D.J. European Society of Medical Oncology Congress; 2002. 2002;2 Oxford University Press, Nice, France
14. Rinehart J.J., Wilding G., Wilson J., et al. A phase 1 clinical and pharmacokinetic study of oral CCI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Grunberg S.M. Annual Meeting of the American Society of Clinical Oncology; 2002. 2002;41a American Society of Clinical Oncology, Orlando, FL
15. Gatzemeier U., Groth G., Butts C., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HERZ-positive non-small-cell lung cancer. Ann. Oncol. 15:(1):2004;19-27
16. Herbst R.S., Hidalgo M., Pierson A.S., Holden S.N., Bergen M., Eckhardt S.G. Angiogenesis inhibitors in clinical development for lung cancer. Semin. Oncol. 29:(Suppl. 4):2002;66-77
17. DeVore R.F., Fehrenbacher L., Herbst R.S., et al. A randomized phase II trial comparing Rhumab VEGF (Recombinant Humanized Monoclonal Antobody to Vascular Endothelial Cell Growth Factor) plus carboplatin/paclitaxel to carboplatin/paclitaxel alone in pateints with stage IIIB/IV non-small cell lung cancer. Perry M.C. Annual Meeting of the American Society of Clinical Oncology; 2000. 2000;485a American Society of Clinical Oncology, New Orleans, LA
18. Johnson D.H., DeVore R., Kabbinavar F., Herbst R., Holmgren E., Novotny W. Carboplatin plus paclitaxel plus RhMab-VEGF may prolong survival in advanced non-squamous lung cancer. Grunberg S.M. Annual Meeting of the American Society of Clinical Oncology; 2001. 2001;315a American Society of Clinical Oncology, San Francisco, CA
19. Hurwitz H., Holden S.N., Eckhardt S.G., et al. Clinical evaluation of ZD6474, an orall active inhibitor of VEGF signaling in patients with solid tumors. Grunberg S.M. Annual Meeting of the American Society of Clinical Oncology; 2002. 2002;82a American Society of Clinical Oncology, Orlando, FL
20. Jansen B., Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol. 3:2002;72-83
21. Yuen A.R., Halsey J., Fisher G.A., et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5:1999;3357-3363
22. Yuen A., Halsey J., Fisher G., et al. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Grunberg S.M. Annual Meeting of the American Society of Clinical Oncology; 2001. 2001;308a American Society of Clinical Oncology, San Francisco, CA
23. Lynch T.J., Raju R., Lind M., et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced non-small cell lung cancer. Grunberg S.M. Proceedings of the American Society of Clinical Oncology; 2003. 2003;623 American Society of Clinical Oncology, Chicago, IL
24. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases biologic activity and clinical implications. J. Clin. Oncol. 18:2000;1135-1149
25. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 93:2001;178-193
26. Bissett D., O'Byrne K.J., von Pawel J., et al. Phase III study of the matrix metalloprotease inhibitor prinomastat in combination with gemcitabine and cisplatinin non-small cell lung cancer. Grunberg S.M. Annual Meeting of the American Society of Clinical Oncology; 2002. 2002;296a American Society of Clinical Oncology, Orlando, FL
27. Shepherd F.A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 20:2002;4434-4439